Protagonist Therapeutics stockPTGX
Protagonist Therapeutics trades at $135.26, 15.9% below its 52-week high (Aug 19, 2026). The price is below its 50-day but above its 200-day average: a pullback within an uptrend. +54.9% year to date, +73.7% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Nov 5, 2026.
Ratings, candles, signals and the screener for PTGX — after you log in
Open the terminalFrequently asked questions about Protagonist Therapeutics
What is the Protagonist Therapeutics stock price?
At the close on Nov 5, 2026: $135.26 (−5.66% on the day). 52-week high: $160.81 on Aug 19, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Protagonist Therapeutics report earnings?
The next quarterly report is on Nov 5, 2026. Last quarter, earnings per share changed +516% year over year, revenue +3,749%.
Does Protagonist Therapeutics pay dividends?
No, Protagonist Therapeutics does not pay dividends.
Where does Protagonist Therapeutics trade and how to buy it?
Ticker PTGX, exchange Nasdaq, listed since 2016. You can buy it through a broker with access to US exchanges.
Should I buy Protagonist Therapeutics now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for PTGX are in the terminal after you log in.